US4243652A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gastrointestinal scanning agent
Assignee: Procter and Gamble Co
•
Filing: 1978-07-14
•
Granted: 1981-01-06
•
Expires: 1998-07-14
Abstract
Abstract Technetium-99m has ideal characteristics for imaging the upper and lower GI tract and determining stomach emptying and intestinal transit time when used with an insoluble particulate material. For example, crystalline and amorphous calcium phosphate particles can be effectively labeled in a one-step process using 99m TcO 4 and SnCl 2 . These labeled particles have insignificant mass and when administered orally pass through the GI tract unchanged, without affecting the handling and density of the intestinal contents. Visualization of the esophageal entry into the stomach, the greater and lesser curvatures of the stomach, ejection into the duodenum, and rates of passage through the upper and lower GI tract are obtained. The slurry of 99m Tc particulate can be given rectally by enema. Good images of the cecum and the ascending, transverse, and descending colon are obtained. Mucosa folds and the splenic and hepatic flexures are visualized. The resilience of the large intestine is also readily visualized by pneumocolonographic techniques.
Inventors
- 👤 Marion D. Francis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:00
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1241; A61K2123/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
25 words
A radiodiagnostic agent, comprising: A. A gamma radiation emitting radionuclide in substantially permanent association with; B. A pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier.
Claim 2
Dependent Claim
25 words
A radiodiagnostic agent, comprising: A. A gamma radiation emitting radionuclide in substantially permanent association with; B. A pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier.
Claim 3
Dependent Claim
16 words
The composition of claim 1 wherein said radionuclide is 99m technetium, 113m indium or 111 indium.
Claim 4
Dependent Claim
15 words
The composition of claim 1 wherein said particulate phosphate carrier is a calcium phosphate compound.
Claim 5
Dependent Claim
14 words
A composition according to claim 3 wherein the calcium phosphate compound is calcium hydroxylapatite.
Claim 6
Dependent Claim
51 words
A composition according to claim 1, comprising: A. From about 100 μCi to about 5000 μCi of 99m technetium in substantially permanent association with; B. From about 50 mg. to about 500 mg. of calcium hydroxylapatite particles having an average particle size of from about 25 A to about 500 A.
Claim 7
Dependent Claim
52 words
A reagent for preparing a 99m Tc-based radio-diagnostic agent for use in the GI tract, or the like, comprising: A. An effective amount of a pertechnetate reducing agent; and B. An effective amount of a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier; said reagent being in the form of a powder.
Claim 8
Dependent Claim
52 words
A reagent for preparing a 99m Tc-based radio-diagnostic agent for use in the GI tract, or the like, comprising: A. An effective amount of a pertechnetate reducing agent; and B. An effective amount of a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier; said reagent being in the form of a powder.
Claim 9
Dependent Claim
22 words
A reagent according to claim 6 wherein the pertechnetate reducing agent is selected from pharmaceutically-acceptable, water-soluble stannous, ferrous, chromous and titanous salts.
Claim 10
Dependent Claim
13 words
A reagent according to claim 7 wherein the reducing agent is stannous chloride.
Claim 11
Dependent Claim
16 words
A reagent according to claim 6 wherein the particulate phosphate carrier is a calcium phosphate compound.
Claim 12
Dependent Claim
14 words
A reagent according to claim 9 wherein the calcium phosphate compound is calcium hydroxylapatite.
Claim 13
Dependent Claim
47 words
A reagent according to claim 6, comprising: A. From about 0.05 mg. to about 0.25 mg. of stannous chloride; and B. From about 50 mg. to about 500 mg. of calcium hydroxylapatite particles having an average particle size of from about 25 A to about 500 A.
Claim 14
Dependent Claim
51 words
A reagent for preparing a 99m Tc-based radio-diagnostic agent for use in the GI tract, or the like, comprising: A. An effective amount of a pertechnetate reducing agent; and B. An effective amount of a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier; and C. An effective amount of a stabilizer.
Claim 15
Dependent Claim
51 words
A reagent for preparing a 99m Tc-based radio-diagnostic agent for use in the GI tract, or the like, comprising: A. An effective amount of a pertechnetate reducing agent; and B. An effective amount of a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier; and C. An effective amount of a stabilizer.
Claim 16
Dependent Claim
22 words
A composition according to claim 12 wherein the pertechnetate reducing agent is selected from pharmaceutically-acceptable, water-soluble stannous, ferrous, chromous and titanous salts.
Claim 17
Dependent Claim
13 words
A composition according to claim 13 wherein the reducing agent is stannous chloride.
Claim 18
Dependent Claim
16 words
A composition according to claim 12 wherein the particulate phosphate carrier is a calcium phosphate compound.
Claim 19
Dependent Claim
14 words
A composition according to claim 15 wherein the calcium phosphate compound is calcium hydroxylapatite.
Claim 20
Dependent Claim
25 words
A composition according to claim 12 wherein the stabilizer is selected from ascorbic acid, or its water-soluble salts, or gentisic acid, or its water-soluble salts.
Claim 21
Dependent Claim
70 words
A reagent according to claim 12, comprising: A. From about 0.05 mg. to about 0.25 mg. of stannous chloride; B. From about 50 mg. to about 500 mg. of calcium hydroxylapatite particles having an average particle size of from about 25 A to about 500 A; and C. From about 0.25 mg. to about 1.0 mg. of a stabilizer selected from ascorbic acid, sodium ascorbate, gentisic acid and sodium gentisate.
Claim 22
Dependent Claim
63 words
A process for preparing a reagent suitable for use as a radiodiagnostic agent in the GI tract, or the like, comprising admixing from about 100 μCi to about 20,000 μCi of a gamma radiation emitting nuclide with a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier, said mixing being carried out in solution, whereby said radionuclide is substantially permanently associated with said carrier.
Claim 23
Dependent Claim
63 words
A process for preparing a reagent suitable for use as a radiodiagnostic agent in the GI tract, or the like, comprising admixing from about 100 μCi to about 20,000 μCi of a gamma radiation emitting nuclide with a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier, said mixing being carried out in solution, whereby said radionuclide is substantially permanently associated with said carrier.
Claim 24
Dependent Claim
47 words
A process for visualizing the GI tract of humans and lower animals, comprising introducing into the GI tract of a human or lower animal a radiodiagnostic agent comprising a gamma radiation emitting radionuclide in substantially permanent association with a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier.
Claim 25
Dependent Claim
47 words
A process for visualizing the GI tract of humans and lower animals, comprising introducing into the GI tract of a human or lower animal a radiodiagnostic agent comprising a gamma radiation emitting radionuclide in substantially permanent association with a pharmaceutically-acceptable, substantially physiologically insoluble, particulate inorganic phosphate carrier.
References Cited (Backward Citations)
US4115536A
Cited
US4115540A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-01-06 | 1984-07-07 | 1985-01-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-01-06 | 1988-07-07 | 1989-01-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-01-06 | 1992-07-07 | 1993-01-06 | $7700.00 | Window Closed / Lapsed |